J. Mayor

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects

C. Endres, S. Alley, Anthony J. Lee, 2020, Journal of clinical pharmacology.

The effective use of plerixafor as a real‐time rescue strategy for patients poorly mobilizing autologous CD34+ cells

W. Bensinger, M. Linenberger, A. Gopal, 2012, Journal of clinical apheresis.

Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).

T. Bekaii-Saab, M. Pishvaian, J. Strickler, 2022, Journal of Clinical Oncology.

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

C. Endres, L. Walker, Anthony Lee, 2022, Clinical Pharmacokinetics.

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

E. Winer, S. Loi, L. Carey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

C. Endres, Anthony J. Lee, L. Walker, 2022, Clinical pharmacokinetics.

MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.

A. Barzi, H. Lenz, J. Marshall, 2021, Journal of Clinical Oncology.

Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists

S. Koontz, R. Tombleson, A. Bryk, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.